2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4060 An integrated prognostic model combining circulating tumor cells, frailty and disease stage improves survival prediction and reveals immune microenvironment remodeling in transplant-ineligible newly diagnosed multiple myeloma

Evangelos Terpos, MD, Ioannis V Kostopoulos, PhD, MSc2, Ioannis Ntanasis-Stathopoulos, MD3, Panagiotis Malandrakis, MD, MSc, PhD4, Pantelis Rousakis5, Nikolaos Tsakirakis, MSc6, Evangelos Eleutherakis-Papaiakovou7, Nikolaos Angelis8, Chrysanthi Panteli9, Panagiotis Bakouros10, Eirini Solia, MD11, Ilias Katsadouros, MD12, Georgia Dimitrakopoulou13, Despina Fotiou, MD, PhD14, Panagiotis Boutsikos, MD15, Magdalini Migkou16, Nikolaos Kanellias, MD, PhD17, Maria Gavriatopoulou, MD18, Efstathios Kastritis, MD19, Ourania Tsitsilonis, MD,PhD20, Meletios-Athanasios (Thanos) C. Dimopoulos, MD21
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 National and Kapodistrian University of Athens, Athens, Greece
13 National and Kapodistrian University of Athens, Athens, Greece
14 National and Kapodistrian University of Athens, Athens, Greece
15 National and Kapodistrian University of Athens, Athens, Greece
16 National and Kapodistrian University of Athens, Athens, Greece
17 National and Kapodistrian University of Athens, Athens, Greece
18 National and Kapodistrian University of Athens, Athens, Greece
19 National and Kapodistrian University of Athens, Athens, Greece
20 National and Kapodistrian University of Athens, Athens, Greece
21 National and Kapodistrian University of Athens, Athens, Greece

Background

Accurate risk stratification in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) remains challenging because disease biology and patient-related characteristics independently influence clinical outcomes. We investigated whether integrating circulating tumor cells (CTCs), frailty status and Revised International Staging System (R-ISS) improves prognostic accuracy, identifies biologically distinct immune microenvironment states and enables individualized prediction of progression-free survival (PFS) and overall survival (OS).

Methods

A total of 425 consecutive patients with TI-NDMM were prospectively enrolled. Peripheral blood CTCs were quantified at diagnosis using standardized next-generation flow cytometry (NGF). Variables independently associated with survival in multivariable Cox regression analysis were incorporated into an integrated prognostic model. One point was assigned to each increasing risk category (R-ISS I/II/III: 1/2/3 points; Frailty Index [FI] fit/intermediate-fit/frail: 1/2/3 points; CTCs <0.02%/≥0.02%: 1/2 points), generating a cumulative score ranging from 3 to 8. Patients were classified into low- (3–4), intermediate- (5–6) and high-risk (7–8) groups. The BM composition of all patients were also assessed using the surface panel of NGF.  

Results

Multivariable Cox regression identified R-ISS (HR 1.79, 95% CI 1.29–2.49; P<0.001), FI (HR 1.67, 95% CI 1.31–2.11; P=0.002) and CTCs (HR 1.58; 95% CI 1.22-1.83; P=0.003) as independent predictors of OS. These variables were therefore combined into an integrated prognostic model. Compared with each individual parameter and all dual-parameter combinations, the integrated model demonstrated superior prognostic discrimination.

The model stratified patients into three groups with progressively inferior outcomes. Median PFS was 53, 40 and 29 months for low-, intermediate- and high-risk patients, respectively (P<0.001), whereas median OS was NR, NR and 39 months, respectively (P<0.0001). Predictive performance was superior to R-ISS, FI or CTCs alone, with C-indices of 0.67 for PFS and 0.72 for OS. Importantly, the integrated model retained independent prognostic significance after adjustment for age, indicating that its predictive value extends beyond chronological aging.

Time-dependent ROC analysis further confirmed the robustness of the model. For OS prediction, the integrated model achieved AUC values of 70.9%, 67.8%, 70.1% and 72.9% at 12, 24, 36 and 48 months, respectively, consistently outperforming each individual model. Based on these findings, individualized nomograms were generated for both PFS and OS, allowing estimation of personalized survival probabilities across clinically relevant time points.

Beyond its prognostic performance, the integrated model identified biologically distinct immune microenvironment profiles. The most prominent differences involved B-cell populations. Median naïve B-cell frequencies progressively decreased from 0.82% in low-risk patients to 0.52% and 0.41% in intermediate- and high-risk groups, respectively, while B-cell precursors demonstrated an even more pronounced reduction (0.19%, 0.08% and 0.01%, respectively). Likewise, the CD27+/CD27− T-cell ratio declined progressively across the three groups (5.55, 4.92 and 3.36, respectively), indicating increasing impairment of adaptive immune homeostasis. Myeloid progenitor cells were also reduced in higher-risk patients (median 1.14%, 1.24% and 0.81%, respectively). These immune changes matched the poorer survival outcomes across the three risk groups, supporting the model and suggesting that increasing clinical risk reflects progressive changes in the immune environment, rather than disease burden alone. 

Conclusions

An integrated prognostic model combining CTCs, frailty status and R-ISS significantly improves risk stratification in TI-NDMM independently of patient age. Beyond its superior predictive performance, the model captures biologically distinct immune microenvironment states characterized by progressive depletion of naïve B cells, B-cell precursors, reduced CD27+/CD27− T-cell ratios and diminished myeloid progenitors with increasing risk. The accompanying nomograms for PFS and OS provide a practical tool for individualized prognostication and support future biologically informed, risk-adapted therapeutic strategies in transplant-ineligible multiple myeloma.

Evangelos Terpos, MD: Swixx - Honoraria; Takeda - Honoraria; Menarini - Honoraria; Johnson & Johnson - Honoraria; Sanofi - Honoraria; GSK - Honoraria; Forus - Honoraria; Bristol Myers Squibb - Honoraria; Antengene - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; EUSA Pharma - Honoraria; Johnson & Johnson - Research Funding; GSK - Research Funding; Sanofi - Research Funding; Menarini - Research Funding; Menarini - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)